Alnylam Pharmaceuticals | ALNY - 销售收入



金融业
股票价格
USD
资产
USD 5.56B
现金及等价物
USD 1.71B
销售成本
USD 298.45M
流动资产
USD 4.62B
流动负债
USD 1.51B
债务
USD 1.27B
EBIT
USD 112.6M
EBITDA
USD 245.34M
员工
2.23K
EPS每股收益
USD 1.84
股本和储备
USD 1.35B
销售毛利
USD 992.69M
债务利息支出
USD 82.05M
利息收入
USD 26.6M
贷款资金
USD 2.47B
市值
USD 29.58B
净收入
USD 164.49M
营业费用
USD 1.06B
营业利润
USD 112.6M
普通股股本
USD 133.73M
PE价格收益
75.64
税前利润
USD 177.81M
销售收入
USD 1.29B
销售和管理费用
USD 347.92M
股票
USD 97.11M
贸易债权人
USD 108.02M
应收帐款人
USD 912.74M


销售 更改 日
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Amgen USD 10.1B 1.48B 2026-06
Arrowhead Research USD 75.23M 1.49M 2026-06
BioCryst Pharmaceuticals USD 218.25M 188.3M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Incyte USD 1.67B 400M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
Moderna USD 100M 289M 2026-06
Neurocrine Biosciences USD 959M 148M 2026-06
Novartis USD 13.11B 750M 2026-03
PTC Therapeutics USD 361M 88M 2026-06
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 12.14B 65M 2026-03
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Takeda JPY 1.22T 130B 2026-06
Tectonic Therapeutic USD 0 0 2024-12
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06
Xencor USD 51.22M 46.71M 2026-06